These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30502634)

  • 1. Synthesis and biological evaluation of 7-(aminoalkyl)pyrazolo[1,5-a]pyrimidine derivatives as cathepsin K inhibitors.
    Petek N; Štefane B; Novinec M; Svete J
    Bioorg Chem; 2019 Mar; 84():226-238. PubMed ID: 30502634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Route to the Synthesis of Novel Pyrazolo[1,5-a]pyrimidines and Evaluation of their Antimicrobial Activity as RNA Polymerase Inhibitors.
    Abdallah AEM; Elgemeie GH
    Med Chem; 2022; 18(9):926-948. PubMed ID: 35236270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
    Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
    Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.
    Rankovic Z; Cai J; Kerr J; Fradera X; Robinson J; Mistry A; Hamilton E; McGarry G; Andrews F; Caulfield W; Cumming I; Dempster M; Waller J; Scullion P; Martin I; Mitchell A; Long C; Baugh M; Westwood P; Kinghorn E; Bruin J; Hamilton W; Uitdehaag J; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1524-7. PubMed ID: 20149657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and BZR affinity of pyrazolo[1,5-a]pyrimidine derivatives. Part 1: study of the structural features for BZR recognition.
    Selleri S; Bruni F; Costagli C; Costanzo A; Guerrini G; Ciciani G; Costa B; Martini C
    Bioorg Med Chem; 1999 Dec; 7(12):2705-11. PubMed ID: 10658575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
    Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
    Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
    Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
    Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
    Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
    Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
    Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
    Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
    Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anticancer evaluation of novel pyrazole, pyrazolo[3,4-d]pyrimidine and their glycoside derivatives.
    Nassar IF; El Farargy AF; Abdelrazek FM; Ismail NSM
    Nucleosides Nucleotides Nucleic Acids; 2017 Apr; 36(4):275-291. PubMed ID: 28323527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.
    Venkatesan G; Paira P; Cheong SL; Federico S; Klotz KN; Spalluto G; Pastorin G
    Eur J Med Chem; 2015 Mar; 92():784-98. PubMed ID: 25633494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
    Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico Analysis and Molecular Docking Studies of Novel 4-Amino-3- (Isoquinolin-4-yl)-1H-Pyrazolo[3,4-d]Pyrimidine Derivatives as Dual PI3-K/mTOR Inhibitors.
    Panchal II; Badeliya SN; Patel R; Patel A; Devaligar A
    Curr Drug Discov Technol; 2019; 16(3):297-306. PubMed ID: 30387396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold.
    Ortuso F; Amato R; Artese A; D'antona L; Costa G; Talarico C; Gigliotti F; Bianco C; Trapasso F; Schenone S; Musumeci F; Botta L; Perrotti N; Alcaro S
    J Chem Inf Model; 2014 Jul; 54(7):1828-32. PubMed ID: 24896223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.